Latest Imexhs (ASX:IME) News

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

IMEXHS Limited has reported a strong finish to FY25, delivering revenue and underlying EBITDA at the top end of its guidance, driven by robust software growth and expanding recurring revenue.

IMEXHS Limited reported a 9% rise in Q3 FY25 revenue and a positive swing to $0.6m underlying EBITDA, reaffirming full-year guidance. Key contract wins and AI-driven efficiencies underpin margin gains despite political uncertainties in Colombia.

IMEXHS Limited has secured a significant one-year contract with Colombian cancer care provider Oncolife to deliver advanced radiology services, leveraging its integrated software and AI tools to enhance diagnostic precision.

IMEXHS Limited reported steady revenue growth and a strategic push to scale its SaaS medical imaging platform, while navigating margin challenges and regulatory risks in Colombia.

IMEXHS reported a steady first half of FY25 with revenue up 4% and annualised recurring revenue climbing 11%, driven by strong adoption of its Aquila+ radiology platform and strategic capital raising.

IMEXHS Limited reported a $3 million net loss for the half-year ending June 2025, driven by a significant goodwill impairment, while annualised recurring revenue rose 11%. The company completed a $2.6 million capital raise to support growth amid ongoing cost optimisation and automation efforts.

IMEXHS Limited reported steady Q2 FY25 revenue with an 11% rise in annual recurring revenue, supported by a $2.6 million capital raise and operational advances including a major Mexican contract win.

IMEXHS Limited has completed a $1 million conditional placement by issuing new shares to directors and their associated entities, following approval at its recent AGM.

IMEXHS Limited reported robust FY24 growth and launched its AI-enabled medical imaging platform Aquila+, setting the stage for expected profitability and accelerated revenue in 2025.

IMEXHS Limited reported modest revenue growth and a 16% increase in ARR in Q1 FY25, alongside the commercial rollout of its Aquila+ radiology platform and a $2.5 million capital raising to fuel expansion.

IMEXHS Limited reported a robust 34% increase in FY24 revenue to $26.5 million, driven by new contracts in Colombia and Peru that boosted its Annual Recurring Revenue to $30 million. Despite a slight EBITDA shortfall due to a bad debt expense, the company highlighted operational improvements and strengthened its regional footprint.